JP2020528878A - がん治療用インターフェロンプロドラッグ - Google Patents
がん治療用インターフェロンプロドラッグ Download PDFInfo
- Publication number
- JP2020528878A JP2020528878A JP2019570445A JP2019570445A JP2020528878A JP 2020528878 A JP2020528878 A JP 2020528878A JP 2019570445 A JP2019570445 A JP 2019570445A JP 2019570445 A JP2019570445 A JP 2019570445A JP 2020528878 A JP2020528878 A JP 2020528878A
- Authority
- JP
- Japan
- Prior art keywords
- ifn
- cancer
- interferon
- nucleic acid
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762522564P | 2017-06-20 | 2017-06-20 | |
| US62/522,564 | 2017-06-20 | ||
| PCT/US2018/037982 WO2018236701A1 (en) | 2017-06-20 | 2018-06-18 | INTERFERON PRODRUCE FOR THE TREATMENT OF CANCER |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020528878A true JP2020528878A (ja) | 2020-10-01 |
| JP2020528878A5 JP2020528878A5 (cg-RX-API-DMAC10.html) | 2021-05-27 |
Family
ID=64737368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570445A Pending JP2020528878A (ja) | 2017-06-20 | 2018-06-18 | がん治療用インターフェロンプロドラッグ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200123227A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3641829A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2020528878A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20200015742A (cg-RX-API-DMAC10.html) |
| CN (1) | CN111050803A (cg-RX-API-DMAC10.html) |
| CA (1) | CA3067539A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018236701A1 (cg-RX-API-DMAC10.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024511387A (ja) * | 2021-03-16 | 2024-03-13 | シートムエックス セラピューティクス,インコーポレイテッド | マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法 |
| JP2024523290A (ja) * | 2021-06-18 | 2024-06-28 | ナミ セラピューティクス, インコーポレイテッド | がんの処置およびその方法における使用のための、マスクされたI型インターフェロン(IFNαおよびIFNβ)を含む融合タンパク質組成物 |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210130430A1 (en) | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| MX2020012251A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina-2 activables y metodos de uso de los mismos. |
| WO2019222296A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| CA3136602A1 (en) | 2019-04-15 | 2020-10-22 | Qwixel Therapeutics Llc | Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer |
| BR112021022666A2 (pt) | 2019-05-14 | 2022-03-29 | Werewolf Therapeutics Inc | Frações de separação e seus métodos e uso |
| CN114341189A (zh) | 2019-06-12 | 2022-04-12 | 奥美药业有限公司 | 全新il-15前药及其应用 |
| AU2020316002B2 (en) * | 2019-07-25 | 2026-05-07 | The University Of Chicago | Compositions and methods comprising protease-activated therapeutic agents |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| AU2021205981A1 (en) | 2020-01-11 | 2022-07-14 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| AU2021254283B2 (en) | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| US20240076355A1 (en) * | 2021-01-14 | 2024-03-07 | AskGene Pharma, Inc. | Interferon Prodrugs and Methods of Making and Using the Same |
| EP4387987A2 (en) * | 2021-08-18 | 2024-06-26 | Werewolf Therapeutics, Inc. | Activatable inteferon polypeptides and methods of use thereof |
| US20240400633A1 (en) * | 2021-09-30 | 2024-12-05 | Orionis Biosciences, Inc. | Split human ifn-gamma and tnf-alpha constructs and uses thereof |
| WO2023060156A2 (en) * | 2021-10-08 | 2023-04-13 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| MX2024004301A (es) * | 2021-10-08 | 2024-04-26 | Cytomx Therapeutics Inc | Construcciones de citocinas activables y metodos combinados. |
| US20240067691A1 (en) * | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| WO2024186193A1 (ko) * | 2023-03-08 | 2024-09-12 | 인제대학교 산학협력단 | 국소적 방사선 치료에서 전신성 항암 치료를 위한 조성물 |
| KR20260026098A (ko) * | 2023-05-12 | 2026-02-25 | 리제너론 파아마슈티컬스, 인크. | 인터페론 수용체 길항제 및 이의 용도 |
| EP4750813A1 (en) * | 2023-07-25 | 2026-06-03 | TJ Biopharma (Shanghai) Co., Ltd. | Masked interferon fusion proteins and uses thereof |
| WO2025201363A1 (zh) * | 2024-03-27 | 2025-10-02 | 高雄医学大学 | 细胞因子阻断抗体及其应用 |
| WO2026158523A1 (en) * | 2025-01-24 | 2026-07-30 | Tj Biopharma (Hangzhou) Co., Ltd. | Masked multifunctional proteins |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001526242A (ja) * | 1997-12-19 | 2001-12-18 | アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ | Ifnar2/ifn複合体 |
| JP2010536370A (ja) * | 2007-08-22 | 2010-12-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| JP2012520059A (ja) * | 2009-02-23 | 2012-09-06 | サイトムエックス セラピューティクス, インコーポレイテッド | プロタンパク質およびその使用方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040014652A1 (en) * | 2000-06-01 | 2004-01-22 | Andre Trouet | Tumor activated prodrug compounds and methods of making and using the same |
| US20100189727A1 (en) * | 2008-12-08 | 2010-07-29 | Tegopharm Corporation | Masking Ligands For Reversible Inhibition Of Multivalent Compounds |
| US11291721B2 (en) * | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
-
2018
- 2018-06-18 JP JP2019570445A patent/JP2020528878A/ja active Pending
- 2018-06-18 EP EP18820121.4A patent/EP3641829A4/en not_active Withdrawn
- 2018-06-18 CN CN201880053451.8A patent/CN111050803A/zh active Pending
- 2018-06-18 WO PCT/US2018/037982 patent/WO2018236701A1/en not_active Ceased
- 2018-06-18 CA CA3067539A patent/CA3067539A1/en active Pending
- 2018-06-18 US US16/624,648 patent/US20200123227A1/en not_active Abandoned
- 2018-06-18 KR KR1020207000744A patent/KR20200015742A/ko not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001526242A (ja) * | 1997-12-19 | 2001-12-18 | アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ | Ifnar2/ifn複合体 |
| JP2010536370A (ja) * | 2007-08-22 | 2010-12-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| JP2012520059A (ja) * | 2009-02-23 | 2012-09-06 | サイトムエックス セラピューティクス, インコーポレイテッド | プロタンパク質およびその使用方法 |
Non-Patent Citations (2)
| Title |
|---|
| CHEM. MED. CHEM., vol. 11, no. 22, JPN6023008478, 2016, pages 2474 - 2495, ISSN: 0005003375 * |
| ORAL MEDICINE, vol. 120, no. 5, JPN6022022241, 2015, pages 594 - 601, ISSN: 0004788935 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024511387A (ja) * | 2021-03-16 | 2024-03-13 | シートムエックス セラピューティクス,インコーポレイテッド | マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法 |
| JP2024523290A (ja) * | 2021-06-18 | 2024-06-28 | ナミ セラピューティクス, インコーポレイテッド | がんの処置およびその方法における使用のための、マスクされたI型インターフェロン(IFNαおよびIFNβ)を含む融合タンパク質組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3067539A1 (en) | 2018-12-27 |
| RU2020101640A (ru) | 2021-07-20 |
| RU2020101640A3 (cg-RX-API-DMAC10.html) | 2021-09-23 |
| EP3641829A1 (en) | 2020-04-29 |
| US20200123227A1 (en) | 2020-04-23 |
| EP3641829A4 (en) | 2021-04-21 |
| KR20200015742A (ko) | 2020-02-12 |
| WO2018236701A1 (en) | 2018-12-27 |
| CN111050803A (zh) | 2020-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200123227A1 (en) | Interferon prodrug for the treatment of cancer | |
| US10479997B2 (en) | Compositions and methods for diagnosis and treatment of prostate cancer | |
| AU2013355379B2 (en) | Immunotherapy with binding agents | |
| CN102917721B (zh) | Wnt拮抗剂和治疗与筛选方法 | |
| EP3202419A1 (en) | Pvrig binding agents that modulate the hippo pathway and uses thereof | |
| AU2019392915B2 (en) | Identification and targeting of tumor promoting carcinoma associated fibroblasts for diagnosis and treatment of cancer and other diseases | |
| EP4161967A2 (en) | B7h3-targeting proteins and methods of use thereof | |
| EA027502B1 (ru) | Антитела против flt3 и способы их применения | |
| EP3548071A1 (en) | Methods for treatment of cancer comprising tigit-binding agents | |
| US20230139944A1 (en) | Targeting alpha3beta1 integrin for treatment of cancer and other diseases | |
| WO2018148378A1 (en) | Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy | |
| EP3373968B1 (en) | Glypican 2 as a cancer marker and therapeutic target | |
| CN117979976A (zh) | 靶向upar的car-t细胞及其用途 | |
| JP2021502329A (ja) | Rhoaドミナントネガティブフォームを使用して癌を治療するための組成物および方法 | |
| ES2278731T3 (es) | Proteinas denominadas fctrx y acidos nucleicos que las codifican. | |
| US11976104B2 (en) | TLR9 ligand trap | |
| JP7599716B2 (ja) | がんおよび他の疾患の診断および処置のための病原性細胞外マトリックスの同定および標的化 | |
| CN119143888A (zh) | 一种融合蛋白及其制备方法与应用 | |
| RU2788736C2 (ru) | Пролекарство интерферона для лечения рака | |
| US20230366030A1 (en) | Methods of detecting an inactivating mutation of pbrm1 in meningioma | |
| WO2005070448A2 (en) | Methods of use for secreted frizzled-related protein 3 (sfrp-3) in the prevention and treatment of disease | |
| WO2025101551A1 (en) | Prostate-specific membrane antigen (psma)-binding peptides and method of use | |
| US20070274988A1 (en) | Kiaa0779, Splice Variants Thereof, and Methods of Their Use | |
| HK40112191A (en) | Glypican 2 as a cancer marker and therapeutic target | |
| WO2023150260A2 (en) | Compounds that target tem8, compositions, and methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200117 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200221 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20210121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210419 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210419 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220601 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220831 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221130 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230302 |